Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Raytheon Technologies

AT&T

It's understandable if you have whiplash from market moves this year. We've seen stocks surge, fall and surge again on the heels of the current Santa rally.

Solid as a Rock: 3 Blue-Chip Stocks for a Stable Portfolio

Southwest Airlines

Medical device maker Medtronic should benefit from a return to normality in the healthcare industry. United Parcel Service ought to experience better growth as macroeconomic conditions improve.

Got $5,000? These 3 Stocks Are Deep-Value Buys Right Now

AbbVie

Pfizer

These companies all have solid histories of dividend increases and are making future dividend payments a priority. You can likely count on them to grow your passive income from year to year.

Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.

Alphabet

The market's recovery could continue into 2024 -- and these stocks should benefit. Medtronic boasts a steady business and an incredible dividend track record.

A Bull Market Is Coming: 2 Top Stocks to Buy Hand Over Fist

Medtronic's recent earnings report has boosted investor confidence, suggesting the worst may be over for the company. The impact of the weight loss drugs on Medtronic's long-term growth prospects is expected to be limited and could be overstated. MDT's valuation isn't cheap relative to its sector peers, but its best-in-class profitability grade likely justifies the premium.

Medtronic: On The Verge Of A Massive Turnaround

Apple

Chevron

Coca-Cola

McDonald's

Microsoft

Procter & Gamble

Charles Schwab

Some of the best long-term investment stocks include companies that are in good financial standing, have a low valuation and pay consistent dividends.

Best Long-Term Investment Stocks to Buy

Medtronic has revamped its business to favor growth. There are other stocks out there offering higher growth rates and longer streaks of payout hikes.

Medtronic Stock: Bull vs. Bear

Palantir Technologies

AST SpaceMobile

The top tech stocks are always a point of contention among investors. Some prefer sticking with reliable companies like the Magnificent 7, while others decry the same for being grossly overvalued.

If You Can Only Buy One Tech Stock in December, It Better Be One of These 3 Names

Medtronic is a well-diversified healthcare company with strong secular growth and pricing power. The company has four major business segments, each contributing over $2 billion in annual revenue. Medtronic's recent financial results have exceeded expectations, and the company has adjusted its full-year guidance upward.

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Brown & Brown

Chubb

Church & Dwight

Hormel Foods

Jack Henry & Associates

Johnson & Johnson

Public Service Enterprise Group

SPDR S&P 500 ETF Trust

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of Dividend Radar stocks and present the 10 top-ranked stocks for further research and possible investment. This month, I'm presenting high-quality stocks with the highest defensiveness scores based on a scoring system developed by David Van Knapp. I ranked candidates by considering, in turn, their Dividend Safety Scores and their Beta measure of volatility.

10 Dividend Growth Stocks For November 2023

Verizon

The stock market is enjoying some holiday cheer. Amid signs that inflation is letting up and the Federal Reserve may finally put an end to its rate hikes, traders are piling into all sorts of investments right now.

3 Top-Rated Value Stocks That Analysts Are Loving Now

Cincinnati Financial

Essex Property Trust

Leggett & Platt

McCormick

NextEra Energy

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

PPG Industries

Stanley Black & Decker

Target

T. Rowe Price Group

Walgreens

Exxon Mobil

The ProShares S&P 500 Dividend Aristocrats ETF continues its streak of exceptional gains in November, through the 24th, the ETF is up 6.87%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 28 months of tracking these strategies, two strategies are beating NOBL, and one continues to outperform SPY.

My Best Dividend Aristocrats For December 2023

AtriCure

DexCom

Shockwave Medical

The article discusses the factors that have led to the undervaluation of the MedTech sector, including the rise in interest rates, opposition to corporate acquisitions by the FTC, and the impact of GLP-1-based treatments. I defend the importance of MedTech interventions and highlight several companies in the sector that are poised for recovery, including DexCom, Medtronic, Shockwave Medical, and AtriCure. The article provides charts and analysis for each of the mentioned companies, suggesting potential buying opportunities for investors.

Buying These 4 Hated Names Devastated By The GLP-1 Hype

Boston Scientific

Edwards Lifesciences

Ozempic could make some medical devices less necessary than before. If that happens, it would lead to lower revenue for the device makers.

Could Ozempic Harm These 3 Medical Device Stocks?

Medtronic has a history of raising its dividend rapidly, but its pace has slowed down. Fiscal second-quarter sales earnings fell slightly, and the company's predictions for the next six months aren't exciting anyone.

Is Medtronic a Good Dividend Stock to Buy Now?

Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT st

Should You Pick Medtronic Stock At $80 After An Upbeat Q2?

Chevron's growing dividend has enabled it to produce enriching returns. Coca-Cola's ability to grow hasn't fizzled out.

$1,000 Invested in These 3 Dividend Stocks Could Make You Rich

After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic NYSE: MDT has finally reached its bottom, and the reversal is on. The Q2 results confirm normalization in the wake of the COVID bubble and a solid trajectory for growth that is nearly irresistible for value-minded income investors.

Medtronic: oversold, overextended high yield reversal in play

The medical-devices specialist published its latest set of quarterly results. Happily for its shareholders, the company managed to grow on both the top and bottom lines and beat analyst estimates.

Why Medtronic Stock Trounced the Market on Tuesday

Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.

Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up

Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Medtronic (MDT) Reports Q2 Earnings: What Key Metrics Have to Say

Medtronic PLC (NYSE:MDT) shares moved higher in early trade on Tuesday as the medical devices company raised its fiscal 2024 sales and profit guidance. For the full year ending in April 2024, it expects organic revenue growth of 4.75% over fiscal 2023, up from its prior guidance of 4.5%.

Medtronic delivers beat and raise for 2Q sending shares higher

Medtronic beat fiscal second-quarter expectations Tuesday and raised its outlook for the year. MDT stock jumped in early trades.

Medtronic Angles To Retake Its 50-Day Line After Topping Quarterly Calls

Medtronic PLC's stock MDT rose 0.8% premarket Tuesday, after the medical device maker posted better-than-expected earnings for its fiscal second quarter and raised guidance. Dublin-based Medtronic posted net income of $909 million, or 68 cents a share, for the quarter to Oct. 27, up from $435 million, or 32 cents a share, in the year-earlier period.

Medtronic's second-quarter earnings top estimates as medical device maker raises guidance

Medtronic on Tuesday raised its annual profit forecast for the second time this year, banking on higher demand for its medical devices as surgery volumes pick up pace.

News for Medtronic Stock (MDT)